文拉法辛治疗抑郁症的临床对照研究

A comparative clinical study for venlafaxine versus fluxetine in the treatment of depression

目的:评价文拉法辛治疗抑郁症的临床疗效和安全性。方法:将102例抑郁症患者随机分为试验组和对照组各51例,试验组用文拉法辛,起始剂量50mg·d^(-1),7～10d加至75～200mg·d^(-1);对照组用氟西汀,起始剂量为20mg·d^(-1),7～10d内加至40mg·d^(-1),两组疗程均为6周。用汉密顿抑郁量表(HAMD)、临床疗效总评量表病情严重程度(CGI—SI)和不良反应量表(TESS)评价疗效和不良反应。结果:试验组完成48例,有效率为83.3%,对照组完成49例,有效率为81.2%,两组有效率差异无显著性(P>0.05),显效时间试验组为(6.7±3.3)d,对照组为(10.2±4.7)d,试验组显效较早(P<0.05)。TESS评分两组差异无显著性(P>0.05)。治疗第6周末两组HAMD和CGI—SI评分差异无显著性,治疗6周末开始两组评分差异无显著性(P>0.05)。结论:文拉法辛起效快,不良反应小,是一种安全有效的抗抑郁新药。

Objective: To assess the efficacy and safety of venlafaxine in the treatment of depression. Methods: 102 patients with depression were randomly administered with venlafaxine (n=51,48 completed) or fluoxetine (n=51,49 completed) for 6 weeks. The initial doses of venlafaxine versus fluoxetine were 50mg versus 20mg daily, and tapered up to 75～200mg versus 40mg daily in 7～10 days. The efficacy was evaluated with HAMD and CGI-SI. The safety profiles were assessed with TESS. Results: The overall efficacy of two treatment groups showed no significant difference (83.3% versus 81.2%,P>0.05). The median response for venlafaxine treatment was on the (6.7±3.3) day and for fluoxetine on the (10.2±4.7) day (P<0.05). Patients treated with venlafaxine experienced the improvement of depression symptoms in the scores of HAMD and CGI-SI as well as TESS at the end of the study compared to patients treated with fluoxetine, which was not significant (P>0.05). Conclusion: Venlafaxine is a new option for the patients with depression.